BRIEF-Prometic's drug efficacy further evidenced in Type 2 diabetic and metabolic syndrome clinical trial

Tue Apr 26, 2016 6:58am EDT
 
Email This Article |
Share This Article
  • Facebook
  • LinkedIn
  • Twitter
| Print This Article
[-] Text [+]

April 26 (Reuters) - Prometic Life Sciences Inc

* Prometic's PBI-4050: efficacy further evidenced in type 2 diabetic and metabolic syndrome clinical trial

* New results from additional patients increase statistical and clinical evidence of efficacy

* Reduction of glycated hemoglobin (hba1c) reaches -0.9% (p=0.0004) in patients with hba1c  8% at baseline Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1-646-223-8780)